Day Two Agenda
7:00 am - 4:00 pm | Boston, MA
Want to see the agenda, speaker faculty and more all in one place? Download the full Event Guide.
7:00 am Registration
7:55 am Chair’s Opening Remarks
Novel Methods for Successful Neoantigen Identification & Real World Application
8:00 am Categorizing Most Effective Neoantigens to Ensure Greatest Clinical Benefits
Synopsis
- Filtering the different neoantigen sub-categories
- Sequencing the whole genome to identify neoantigens arising from genomic rearrangements
- Identifying the different categories of antigens and rationalizing the most preferred subset
8:30 am Screening the RNA Space for Frameshift Neoantigens
Synopsis
- Sharing an efficacy readout for a preventative cancer vaccine trial
- Predicting before treatment, who will respond to immunotherapeutics and who will not
9:00 am Vaccination Against Shared Neoantigens Induced in Recurrent & Future Tumors
Synopsis
- Common neoantigens are induced in disseminated tumor lesions and resident dendritic cells by targeted siRNA inhibition of the peptide transporter TAP
- Using broadly applicable chemically synthesized oligonucleotides to vaccinate against induced neoantigens which inhibits tumor growth in recurrent and premalignant models
- Vaccination against induced neoantigens will benefit the 70-80% of cancer patients that do not express or express too few mutation-derived neoantigens
9:30 am Identification of Novel pHLA Targets for Solid Tumor
Synopsis
- Advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
- Strategies to find the most prevalent and immunogenic pHLA targets in tumors of CPI responders
- Selection of self-antigen targets with highest tumor vs normal ratios to avoid off-tumor, on-target toxicities of TCR based therapies
10:00 am Morning Break & Networking
Diving into the Second Wave of Immune Response Successes in Trials
10:30 am Session Reserved for Cayman Chemical
11:00 am Immune Camouflaging in Tumors: Implications for Neoantigen Vaccines
Synopsis
- JanusMatrix™, integrated in the Ancer® neoantigen discovery platform, is a specialized in silico tool used to distinguish effector from inhibitory neoantigens
- Ancer® analysis of tumors derived from nivolumab-treated melanoma patients reveals patterns consistent with immune camouflaging: lowered immunogenicity and increased tolerogenic signals
- Relevant neoantigen targets may be harder to identify once patients are treated with checkpoint inhibitors. Neoantigen vaccines may be better administered prior to checkpoint inhibitor therapy
11:30 am Session Reserved for Adaptive Biotechnologies
12:00 pm Lunch & Networking
Combinations with Immune Checkpoint Inhibitors to Enhance Vaccine Effects
1:00 pm Insights into Combination Therapies of Neoantigens and Checkpoint Inhibitors for More Successful Cancer Cures
Synopsis
- Showing what strategies have been developed in combination with checkpoint inhibitors
- Discriminating the value of the vaccine versus the checkpoint inhibitor
- Uncovering the best pre-clinical designs to address issues associated with early stage and late stage cancer
1:30 pm New Class of Antigen-Specific Cancer Active Immunotherapies based on an Off-the-Shelf Antigen Presenting Cell line (PDC*line)
Synopsis
- PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
- PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
- Applying the technology for any cancer
2:00 pm Neoantigen Based Monoclonal Antibodies in Combination with Checkpoint Inhibitors
Synopsis
- Identifying tumor neoantigens
- Determining the function of antibodies targeting the neoantigens
- Justification for combining with checkpoint inhibitors
2:30 pm Afternoon Break & Networking
Comparing Platform Approaches to Challenge Our Understanding & Decision Making
3:00 pm Roundtable Mastermind Session – Weighing the Pros & Cons of Different Methods to Prosecute Neoantigen Targets
Synopsis
- Comparing the various approaches and platforms used to target neoantigens
- Discussing different types of platforms including RNA, DNA or peptides as there is currently no real incentive to make a decision
- Reviewing other therapies being developed for more successful identification
- Challenge your thoughts on shared vs. individualized approaches
3:30 pm Ensuring Effective Cross-Presentation of Neoantigens to Induce a Broad & Strong CD8 T Cell Response
Synopsis
- Optimize long-lasting delivery of neoantigens to dendritic cells
- Cross-presentation of neoantigens to stimulate broad CD8 T cell responses
- Correlation of immune responses and clinical responses